The suppression of ERBB2 by siRNA in tamoxifen-resistant breast cancer cells resulted in a decrease in the proliferative ability of the cells, which reconfirms the involvement of the ERBB2/ERBB3 pathways in the development of chemoresistance to breast cancer cells. Here, ERBB2 is linked to breast carcinoma.